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The inﬂuenza virus subtype H5N1 has raised con-
cerns of a possible human pandemic threat
because of its high virulence and mutation rate.
Although several approved anti-inﬂuenza drugs
effectively target the neuraminidase, some
strains have already acquired resistance to the
currently available anti-inﬂuenza drugs. In this
study, we present the synergistic application of
extended explicit solvent molecular dynamics
(MD) and computational solvent mapping (CS-
Map) to identify putative ’hot spots’ within ﬂexi-
ble binding regions of N1 neuraminidase. Using
representative conformations of the N1 binding
region extracted from a clustering analysis of
four concatenated 40-ns MD simulations, CS-Map
was utilized to assess the ability of small, sol-
vent-sized molecules to bind within close proxim-
ity to the sialic acid binding region. Mapping
analyses of the dominant MD conformations
reveal the presence of additional hot spot regions
in the 150- and 430-loop regions. Our hot spot
analysis provides further support for the feasibil-
ity of developing high-afﬁnity inhibitors capable
of binding these regions, which appear to be
unique to the N1 strain.
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The avian influenza virus type A, especially subtype H5N1, is
becoming the world's largest pandemic threat because of its high
virulence and lethality in birds, quickly expanding host reservoir,
and high rate of mutation (1). The virus functions in combination
with two major membrane glycoproteins: hemagglutinin (HA) and
neuraminidase (NA), which together play important roles in the
interactions with host cell surface receptors. While HA mediates
virion (i.e. viral particle) entry into the cell, NA facilitates viral shed-
ding by cleaving the sialic acid linkage formed between the HA and
sialic receptors on the surface of the host cell (2). Several approved
anti-influenza drugs effectively target NA, which cleaves these ter-
minal sialic acid residues and facilitates the release of viral progeny
from infected cells (3). However, antigenic drift has given rise to
new strains that are resistant to existing NA inhibitors, and anti-
genic shift is resulting in new virulent subtypes of the flu virus,
underscoring the need to design novel NA and HA inhibitors that
can be combined for optimal prophylaxis and treatment.
Neuraminidase enzymes are phylogenetically categorized into two
groups: group-1 includes N1, N4, N5, and N8 and group-2 includes
N2, N3, N6, N7, and N9 (4). Although active site residues are lar-
gely conserved across both the groups, different NA subtypes exhi-
bit varied drug susceptibility (5) and resistance profiles (6,7).
Currently available NA inhibitors, including oseltamivir (marketed as
Tamiflu, Roche Pharmaceuticals, Basel, Switzerland) and zanamivir
(marketed as Relenza, GlaxoSmithKline, Brentford, London, UK),
have been designed against crystal structures of group-2 enzymes
[Ref. (3) and references therein]. Tamiflu, which has been stockpiled
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orally available drug that is effective against H5N1; therefore, addi-
tional drug discovery efforts against this enzyme are exceptionally
well-motivated.
The first crystal structures of a group-1 NA in apo form and in com-
plex with currently available drugs (8) revealed that although the
binding pose of oseltamivir (Tamiflu) was similar to that reported in
previous crystallographic complexes (9,10), the 150-loop adopted a
distinct conformation, opening a new cavity adjacent to the active
site. Under certain crystallization conditions, however, the 150-loop
adopted the same closed conformation as previously seen in
group-2 NA structures, suggesting that a slow conformational
change may occur upon inhibitor binding (8). Importantly, previously
published group-2 NA structures have only reported the 150-loop in
the closed conformation (9,10). Therefore, the new structural obser-
vation of the 150-loop in the open conformation by Russell et al.
(8) was postulated to be able to be exploited in the development of
more effective drugs against N1. However, standard X-ray crystal-
lography experiments only provide a single snapshot of the struc-
ture, making the interpretation of dynamical properties a difficult
task and naturally motivating further studies that are able to inves-
tigate and characterize dynamics.
Molecular dynamics (MD) simulation is a useful theoretical tool to
study the properties of biomolecular systems with atomic resolution
based on classical mechanics (11–13). They complement experimen-
tal results by providing distributions and time series of any physically
definable observable, within force field accuracy and finite sampling
limitations. Extensive all-atom explicit solvent MD simulations of the
apo and oseltamivir-bound (i.e. holo) systems revealed that the 150-
loop and adjacent binding-site loops may be even more flexible than
observed in the crystal structures (14). In the apo simulations, the
150-loop was observed to open to a greater extent than in the X-ray
structures, and its motion was often coupled to an outward move-
ment of the adjacent 430-loop. These coupled motions significantly
expanded the active site cavity, increasing its solvent-accessible sur-
face area as compared with both open and closed crystal structures.
It was postulated that topological changes and additional expansion
of the N1 inhibitor-binding pocket revealed by the MD simulations
could potentially play an important role in the rational design of
inhibitors for N1 (14).
In this work, we present new druggable hot spots, i.e. binding sub-
regions that account principally for the ligand-binding energy,
revealed in the N1 MD simulations by computational solvent map-
ping (CS-Map) (15,16). Originally developed for binding-site identifi-
cation, the CS-Map algorithm replicates the experimental Multiple
Solvent Crystal Structures (MSCS) method developed by Mattos
et al. (17,18), where it was shown that consensus binding locations
of co-crystallized solvent molecules are highly predictive of binding
regions. Using only X-ray structures as input, numerous studies uti-
lizing CS-Map have shown that the method accurately reproduces
the results of MSCS experiments in addition to identifying impor-
tant binding features for other well-studied proteins. The CS-MAP
algorithm differs from similar methods such as GRID (19) and
MCSS (20) in three major respects: (i) the initial rigid body search
provides better sampling of protein surface regions with favorable
electrostatics and desolvation than grid search or local minimiza-
tion; (ii) the scoring potential accounts for desolvation and ligand
flexibility; and (iii) the docked ligand positions are clustered and
the clusters are ranked on the basis of their average binding affinity.
Importantly, this allows us to capture consensus sites rather than
the binding sites of individual probes. The combination of these ele-
ments yields an algorithm that shows remarkable robustness
against variations in the protein structure and changes in energy
parameters (16).
In a recent study performed by Landon et al. (21), CS-Map was
applied to identify hot spots within druggable protein binding
regions and showed excellent agreement with biophysical experi-
ments, where the authors were able to successfully use CS-Map to
identify hot spots for a range of important pharmaceutical targets.
The study highlighted the accurate identification of a novel hot
spot within the peptide-binding region of renin that was recently
discovered at Novartis (Novartis, Basel, Switzerland) (22). After
more than 20 years of research efforts, the discovery of this hot
spot led directly to the development of the first orally bioavailable
FDA-approved renin inhibitor. The same CS-Map-based hot spot
study reported excellent correspondence between the hot spots
predicted for the FK-506 binding protein and ketopantoate reduc-
tase to those originally identified by NMR (23) and isothermal titra-
tion calorimetry experiments (24), respectively. The authors of this
study concluded that CS-Map is a valuable complement for bio-
physical experiments, in which the data resulting from mapping
studies can be used to design and conveniently select drug discov-
ery experiments.
Here, we apply CS-Map to identify additional hot spots within the
sialic acid binding region of N1 using MD-generated ensembles as
input. The application of CS-Map in conjunction with MD simula-
tions is conceptually similar to the so-called 'dynamic pharmaco-
phore' technique originally developed by Carlson et al. (25), which
was one of the first experimentally verified methods to account for
receptor flexibility in structure-based drug design through the use of
MD simulations. This technique has been extended by the Carlson
group to include the use of structural ensembles derived via NMR
and X-ray crystallography, termed the 'multiple protein structure
models' approach (26). Although both the dynamic pharmacophore
method and the one described herein utilize small molecule probes
to investigate the effects of structural flexibility on ligand binding,
the CS-Map technique has the advantage of being directly compara-
ble with MSCS experiments. As emphasized by Mattos and Ringe
(15), the major problem with approaches exemplified by GRID (16)
and MCSS (17), is that they result in too many energy minima on
the surface of the protein, rendering it difficult to determine which
of the minima are actually relevant. A careful study comparing the
results of mapping calculations with X-ray structures of thermolysin
determined in four different organic solvents (27) shows that both
GRID and MCSS find minima close to the experimentally observed
positions, but the closest minima are generally not among those
with the lowest free energies, resulting in false positives (i.e. con-
formations with favorable energy which are not located near any
experimentally observed binding site). However, it has been recently
reported that re-ranking MCSS results with a potential that accounts
for solvation improves agreement with experimental data (28).
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ence- (RMSD-) clustering algorithm to reduce the structural redun-
dancy in the MD ensemble. Previous studies tackled this same
computational issue using different algorithms (14,29,30). However,
we note that the present study is based on considerably longer MD
trajectories – equivalent of 160 ns – therefore providing an exten-
sive sampling of the receptor configurational space. The combina-
tion of techniques in this work presents an efficient method to map
target hot spots based on a reduced and representative ensemble of
receptor structures, and it represents a novel application of existing
computational methods for the investigation of protein–ligand inter-
actions in the presence of significant conformational flexibility
within a ligand-binding site.
The RMSD-clustering analysis of the explicitly solvated 40-ns tetra-
mer MD simulations yielded a set of 10 structures representing the
apo ensemble and 5 structures representing the holo ensemble. A
series of mapping analyses were subsequently performed on the
representative snapshots. The results suggest that low-energy hot
spots within the 150- and 430-loop regions, determined by consen-
sus binding positions of fragment-sized molecules, may provide
additional opportunities for drug discovery that could potentially
mitigate the effects of drug resistance. Furthermore, this study tack-
les two major methodological issues. First, it demonstrates the
benefit role of employing MD simulations to capture receptor flexi-
bility. Second, it provides a framework to apply CS-Map in conjunc-
tion with reduced and representative MD receptor ensembles to
predict the binding of molecules within flexible regions with
increased accuracy and efficiency.
Methods
Apo system setup
The crystal structures used in this study were 2HU0 for the osel-
tamivir-bound system and 2HTY for the apo system (8). Protonation
states for histidine residues were defined at an apparent pH 6.5
using the PDB2PQR web server (31). All crystallographically resolved
water oxygen positions were retained in the apo system, as well
as Ca
2+ ions, which are required for optimal NA function (32). To
mimic future experimental inhibition assay conditions, a 20-mM
NaCl salt bath was introduced. The simulated system contained
112 311 atoms. Additional details on the simulation setup can be
found elsewhere (14).
Holo (i.e. oseltamivir-bound) system setup
The 2HU0 structure had a single oseltamivir molecule bound in the
active site of chain B (8). To introduce the oseltamivir within each
of the other chains, chain B was aligned to chain A, C, and D by
superimposition of the backbone Ca-atoms and the resulting trans-
formation matrix was also applied to the oseltamivir molecule. As
no water molecules or ions were reported in the 2HU0 structure,
we structurally aligned the 2HTY and 2HU0 systems and kept all
crystallographic water molecules that did not clash with oseltamivir
in the binding pocket. The Ca
2+ ions were also retained as they are
required for proper function. Amber9 was used to set up the osel-
tamivir-bound system using an identical protocol to the apo system
(see earlier), with the exception of the additional oseltamivir para-
meters. Oseltamivir was parameterized as described in Ref. (14).
The composite tetrameric oseltamivir-bound system, comprising one
oseltamivir molecule in each of the four active sites and calcium
ions in 20-mM NaCl salt bath, contained 112 457 atoms.
Molecular dynamics simulations
The energy of apo and holo systems were minimized for 5 · 10
4
steps using NAMD version 2.6b1 (http://www.ks.uiuc.edu/Research/
namd/) (33). During the first phase of the minimization, only
hydrogen atoms were relaxed for 5 · 10
3 steps, holding all other
atoms fixed. Hydrogen atoms, water molecules, and ions were
relaxed during additional 5 · 10
3 steps. In the last cycle, the protein
backbone was fixed, minimizing all other atoms for additional
5 · 10
3 steps. No constraints were applied to the final 2.5 · 10
3
steps. The system was then equilibrated at 310 K in the (N,p,T)
ensemble, using rectangular periodic boundary conditions and the
particle mesh Ewald approach to evaluate electrostatics (34). All
hydrogen bond lengths were constrained using the RATTLE algorithm
(35), thus allowing a 2-fs integration timestep. A multiple time-step-
ping algorithm was utilized, where bonded interactions were evalu-
ated at every timestep, short-range non-bonded interactions were
evaluated at every two timesteps, and long-range electrostatic inter-
actions were evaluated at every two timesteps. A cutoff of 14  
was enforced for the non-bonded calculations, including a switching
function at 12  . The first 1-ns period was divided into a series of
four 2.5 · 10
5 step runs, where harmonic constraints were employed
with 1-fs timesteps to gradually relax the system before the free
sampling phase. A harmonic constraint force constant of 4.0 kcal⁄
mol⁄ 
2 was applied to protein backbone atoms with scaling factors
of 1.0, 0.75, 0.50, and 0.25 for the sequential segments, respectively.
Free dynamics were subsequently performed using a 2-fs timestep,
for a total of 40 ns for each system. Trajectories were generated on
the DataStar machine (San Diego Supercomputing Center, University
of California, San Diego, La Jolla, CA, USA) (benchmark time of
0.3 days⁄ns using 112 parallel processors).
RMSD-clustering to extract representative MD
structures
To generate a reduced, representative set of N1 structures for the
CS-Map calculations, RMSD conformational clustering was per-
formed based on a previously reported clustering algorithm (36)
as implemented in the rmsdmat2 and cluster2 programs of the
GROMOS++ analysis software (37), part of the GROMOS05 software for
biomolecular simulation (http://www.igc.ethz.ch/GROMOS). The
same procedure has been recently applied to the context of protein
surface loops (38) and of an improved relaxed complex method
for drug design (39).
For the apo and oseltamivir-bound simulations, each chain of the
tetramer was extracted at 10-ps intervals over the 40-ns simulation.
A total of 1.6 · 10
4 trajectory structures for each simulation were
superimposed using all Ca-atoms to remove overall rotation and
translation. The RMSD-clustering was performed on the subset of
62 residues that line the entire binding-site area, which we define
here as the binding-site residues: 117–119, 133–138, 146–152, 156,
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347, 368, 401, 402, and 426–441 (Figure 1). These residues were
clustered into batches of similar configurations using the backbone
atom-positional RMSD of all atoms (including side chains and
hydrogens) as the similarity criterion. A cutoff of 1.3   was chosen
after evaluation of the dependence of cluster populations against
the total number of clusters found for each simulation using a cut-
off in the range 1.0–1.5  . Next, for both the apo and holo simula-
tions, hydrogen bonding was monitored alternatively using
structures from the X-ray crystallographic models, the entire MD
ensemble, or the structures belonging to each of the three most
populated clusters.
Computational solvent mapping
The CS-Map algorithm is described in the sequence below.
Required input is a protein structure, where prior to initiation, any
bound ligands and⁄or water molecules are removed. The 14 organic
probes utilized in this study correspond to those employed in the
previous hot spot analysis (21) (Figure 2). Mapping simulations
were performed on the IBM Blue Gene supercomputer at Boston
University, Boston, MA, USA (http://www.ibm.com), where the aver-
age CPU time for the first two steps averages 15 min using 220
processors.
Rigid body search
For each probe, we generate 222 initial positions on the protein
surface along vectors originating from the center of the protein at
every 18 . From each of these 222 points, we launch 30 simplex
(40) runs with initial simplexes randomly selected around each
point, resulting in 6660 docked conformations. Simplex moves are
evaluated according to the energy equation:
DGs ¼ DEelec þ DGdes þ Vexc:
The terms in the equation denote the Coulombic contribution of the
electrostatic energy, the desolvation energy, and the excluded vol-
ume penalty, respectively. The electrostatic energy (DEelec) is the
summation over all probes atoms of the product of the electrostatic
field of the solvated protein, denoted as F, at a particular probe
position, determined by a finite-difference Poisson–Boltzmann
method (41,42), and the charge q of the probe atom. Mathematically,
DEelec ¼
X
i
Uiqi
The desolvation term is calculated in accordance with the atomic
contact potential (ACP) model (43), where partial charges are calcu-
lated using Quanta (http://www.accelyrs.com). The excluded volume
term (Vexc) is set to zero if the probe does not overlap the protein.
Reﬁnement of docked conformations
Resulting from the rigid body search are 6660 protein-probe com-
plexes that undergo further minimization. At this stage, a van der
Waals energy is included in the free energy calculation DG =
DEelec + DEvdw + DGdes*. The new desolvation term includes the
solute–solvent van der Waals interaction energy. The electrostatic
and desolvation terms are calculated using the analytic continuum
electrostatic (ACE) model (44); each protein-probe minimization is
performed using the Newton–Rhapson method implemented in
CHARMM (45). While the protein is held rigid during the minimiza-
tion, the probe molecules are allowed to be flexible. A maximum of
1000 minimization steps are needed; often fewer steps are required
for convergence of DG.
Probe clustering, scoring, and ranking of
conformations
Once the probes are minimized in step two, they are clustered
based on their residue interactions. Clusters are initiated by seeding
with an unclustered probe with the lowest free energy. Next, the
Figure 1: The 62 residues lining the N1 binding site used for
RMSD-based clustering are shown with their Ca's shown in space-
filling. They encompass the 150- and 430-loops. Tamiflu is shown
bound in the active site, colored by atom-type.
Figure 2: Probe set used for CS-Map.
Hot Spots in Avian Inﬂuenza Neuraminidase H5N1
Chem Biol Drug Des 2008; 71: 106–116 109remaining unclustered probes are searched to find the probe with
the lowest distance score D to the seed probe. The score D is
determined by the equation
D ¼ 1  ð u   vÞ=ð u jj v jj Þ ;
where u and v are binary strings representing the interactions for
each ligand. If this score is below 0.35, then the probe is added
to the cluster. The threshold score of 0.35 was chosen such that
unclustered probes could be assigned uniquely to one cluster. Once
more than two probes are part of the cluster, additional probes are
added to the cluster by checking that the average distance score
between the new probe and all existing members is below 0.35. If
the new probe has an average score above 0.35, then the probe is
rejected and a new search begins. Once all probes are checked for
admittance to a cluster and no additional probes can be added, a
new cluster begins by repeating the process. After initial creation of
clusters, probes are re-clustered such that if the average overlap
score D of two clusters can be improved by moving a probe from
one cluster to the other, then the probe is moved. Subsequent to re-
clustering, clusters consisting of less than 20 probes are removed.
For each remaining cluster i, the probability pi is calculated based
on a partition function Q, which is the sum of Boltzmann factors
over all conformations j:
pi ¼ Qi=Q
where
Q ¼
X
j
expð DGj=RTÞ:
and Qi is obtained by summing the Boltzman factors over conforma-
tions in the i
th cluster only. The mean values DG of free energy of
cluster is calculated by the formulation
hDGii ¼
X
j
pijDGj
where
pij ¼ expð DGj=RTÞ=Qi
Determination of consensus sites
From each of the five lowest free energy clusters for each probe,
the lowest free energy conformation is selected and superimposed
with all chosen clusters. The locations on the protein where clus-
ters of different probe types aggregate are termed 'consensus'
sites, and these positions on the protein are considered to be puta-
tive binding pockets subject to further evaluation.
Results and Discussion
Clustering of MD snapshots to generate a
reduced and representative receptor ensemble
To distill the most dominant configurations of N1 from the MD sim-
ulations, RMSD-based clustering was performed on snapshots
which were extracted from the trajectories for every 10 ps. Although
the tetramer N1 was used in the simulations, the clustering
analyses were carried out on individual monomer protein chains.
Therefore, each 40-ns tetramer simulation yielded the equivalent of
four times the monomer sampling (160 ns), and 1.6 · 10
4 structures
for each system were employed in the analyses.
For the apo simulation, the 1.3-  cutoff resulted in a total of 51
clusters, with 90% of the ensemble represented by 10 clusters
(Supplementary Material (SM) Figure 1A). In comparison, the holo
simulations revealed an overall less flexible system, as the same
cutoff yielded a total of 27 clusters, with 90% of the ensemble
being represented by five clusters ((SM) Figure 1B). For both the
apo and holo simulations, although the entire binding-site region
was used in the clustering, the greatest structural diversity is found
in the 150- and 430-loop areas (Figure 3), indicating that these
areas are particularly flexible.
To add physical and structural insight to the resulting clusters, a
hydrogen-bonding analysis was performed on the 150-loop region
(comprised of residues 140–152) for the X-ray crystal structures, over
both the entire concatenated trajectory of the four monomers, and
the structures within each of the most dominant clusters (Table 1).
The crystal structures have five fully formed hydrogen bonds between
residues in the 150-loop region: K143–D142, H144–D142, S145–
D142, N146–K143, and T147–N146. Hydrogen bond occurrences dif-
fer between the apo and holo simulations. Additional hydrogen bonds
involving H144–D142 and S145–D142, which are not present in the
crystal structures, form transiently throughout the 160 ns of MD.
AB
Figure 3: The central member
structures of the dominant clusters
from the apo and holo molecular
dynamics ensembles are shown in
A) and B), respectively. Structures
are colored by RMSD per residue
of each cluster structure to the
2HU4 crystal structure (which is
not shown). Note the two most
variable regions in the binding site
are the 150- and 430-loop regions.
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ing approximately 20% of the total apo ensemble, SM Figure 1A) is
characterized by seven hydrogen bonds in the 150-loop area.
Although the hydrogen bond between T147 and N145 is lost, high
occupancies of hydrogen bonds in the D142–K143–H144 region con-
tribute to the overall stability of this structure. The 150-loop in the
first cluster for the apo simulations is significantly more open than
in the 'open-loop' crystal structure published in Ref. (8). It is interest-
ing to note that this so-called 'wide-open' structure (14) seems to be
energetically and structurally stabilized by locally-formed hydrogen
bonds. The second most highly populated cluster also accounts for
nearly 20% of the ensemble (SM Figure 1A) and the additional sta-
bility of the T147–N146 hydrogen bond. Notably, although several
hydrogen bonds are less often formed on average, as compared to
the first cluster the S145–D142 hydrogen bond is present over the
entire cluster set. From a structural standpoint, the second cluster
represents the open-loop crystal structure (PDB 2HTY). The third
most highly populated cluster is, on an average, lacking the N146–
K143 hydrogen bond and exhibits overall a reduced occupancy of
hydrogen bonds. This cluster represents nearly 20% of the total apo
ensemble, and its central member structure is similar to the closed-
loop crystal structure (Figure 3).
In the holo simulations, the most highly populated cluster repre-
sents nearly 40% of the overall ensemble and has more hydrogen
bonds than the second or third cluster (totally seven hydrogen
bonds). These interactions persist throughout the simulations, as
indicated by the high percentages for each hydrogen bond (Table 1).
Structurally, the most dominant cluster in the holo simulations is
similar to the open-loop crystal structure (8). The second cluster,
which is structurally similar to the fully-open MD structure, is
defined by a loss of the T147–N146 hydrogen bond and a marked
reduction in the persistence of the hydrogen bonds between N146–
K143 and S145–D142. The second cluster represents slightly more
than 20% of the overall holo ensemble. By comparison with the
apo simulation, the clustering results suggest that the presence of
oseltamivir in the active site tends to decrease the amount of time
the 150-loop samples wide open-loop configuration. The third clus-
ter for the holo simulation is structurally similar to the closed-loop
conformation and represents approximately 15% of the overall holo
ensemble. This cluster of structures is defined by a loss of the
S145–D142 hydrogen bond and markedly decreased values for the
K143–D142 and H144–D142 hydrogen bonds relative to both the
other clusters.
Mapping analysis of the apo and holo N1 X-ray
structures
Using the chemically diverse probe set defined in Figure 2, mapping
analyses were performed on the N1 apo and holo structures avail-
able from the PDB (2HTY, 2HU0, and 2HU4). It is important to note
that although mapping was performed using the entire structures
as input, our analyses here are restricted to those consensus
sites found within close proximity to the sialic acid binding region.
As the apo conformation of N1 is nearly identical to the open holo
conformation, here, we only discuss those results obtained for the
open and closed holo conformations.
Figure 4A represents consensus sites resulting the open N1 struc-
ture (2HU0), with cluster representatives colored in magenta, reveal-
ing distinct hot spots located in the sialic acid, the 430-loop, and
the 150-loop regions of the binding pocket. In Figure 4B, hot spots
are distinguishable in the sialic acid and 430-loop binding regions
of the closed holo conformation; while in the open holo structure,
the disappearance of a consensus site in the 150-loop region is
observed upon loop closure. Average rankings of the sialic acid,
430-loop, and 150-loop consensus sites when compared with all
others found along the protein surface are fourth, second, and third,
respectively. Rankings are determined based on the number of low-
energy probe clusters comprising the consensus site.
Based on the direct relationship established between consensus
site ranking and druggability in previous studies, we hypothesize
that binding regions formed in the 430- and 150-loop regions may
provide novel opportunities for lead design. Extension of molecules
from the sialic acid binding region into the 430-loop binding region
Table 1: Intramolecular hydrogen bonds (averaged over the four monomers in N1) for the 150-loop
H-bond X-ray structure Trajectory First cluster Second cluster Third cluster
Donor–Acceptor 2HTY 2HU0 Apo Holo Apo Holo Apo Holo Apo Holo
K143:N–D142:OD1 100 100 48 53 56 59 43 50 30 31
H144:N–D142:OD2 100 100 74 90 81 97 74 100 52 51
H144:ND1–D142:OD1 – – 47 – 46 – 44 – 51 –
H144:ND1–D142:OD2 – – 69 79 84 79 58 100 41 100
S145:N–D142:O 100 100 98 99 94 100 100 96 96 100
S145:OG–D142:O – – 69 62 92 97 96 17 32 –
N146:N–K143:O 100 100 70 79 96 97 96 34 – 61
T147:N–N146:OD1 100 100 51 45 – 81 78 – 86 32
The first column shows the hydrogen bonds (donor:atom–acceptor:atom). The second column shows the relative occurrences (in %) for the 150-loop (residues
140–152) based on the crystal structures. Third and fourth columns report corresponding occurrences over the ensemble of structures from the MD simulations.
The following columns show occurrences, calculated from structures in only the first, second, and third most-populated conformational clusters. Hydrogen bonds
are defined to have a maximum hydrogen-acceptor distance of 3.5   and a minimum donor–hydrogen–acceptor angle of 120 . Only hydrogen bonds occurring
for at least 10% of the simulation are shown.
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position than molecules designed to bind within the 150-loop
region; however, molecules that stabilize the open confirmation
150-loop may also be a viable approach to lead design.
Mapping analysis of reduced and representative
apo and holo MD ensembles
Mapping of the 10 apo MD and 5 holo MD representative confor-
mations was performed to explore the effects of receptor flexibility
on the formation of hot spots within the 150- and 430-loop binding
regions. For each mapping analysis, the entire surface of the pro-
tein was utilized by CS-Map. On an average, seven densely-popu-
lated (£10 probe clusters) consensus sites were found for each apo
conformation and six were uncovered for each holo conformation.
Figure 5 illustrates consensus sites formed within the binding
regions of the apo and holo MD ensembles, where in Figure 5A,
mapping results for the 10 apo conformations are superimposed
onto PDB 2HTY, and in Figure 5B, mapping data for the five holo
conformations are superimposed onto PDBs 2HU0 and 2HU4. Similar
to mapping results for the X-ray structures, hot spots emerge within
the sialic acid, 150- and 430-loop regions of both the apo and holo
AB
Figure 5: Consensus sites resulting from mapping the A) 10 apo MD structures and B) 5 holo MD structures. Shown all together for each
ensemble, low-energy cluster representatives are colored in magenta, and Tamiflu is shown bound in the active site, colored by atom-type.
Mapping results for the apo ensemble are superimposed onto the X-ray structure 2HTY, while mapping results for the holo ensemble are
superimposed onto the two holo X-ray structures, PDBs 2HU0 and 2HU4. Extended consensus sites in the 430-loop (highlighted in red) and
150-loop (highlighted in green) result from mapping the MD ensembles as compared to the X-ray structures; in the case of holo MD ensem-
ble, a hot spot in the 150-loop is only formed when the MD simulations are used as input. This data demonstrates the utility of using
MD-generated conformational ensembles to identify hot spots in flexible loop regions.
AB
Figure 4: Consensus sites resulting from mapping the A) open structure (PDB 2HU0) and B) closed structure (2HU4) of holo N1. Low
energy cluster representatives are colored in magenta, with Tamiflu superimposed and colored by atom-type. In the open and closed confor-
mations a consensus site is observed in the 430-loop region (highlighted in red); however, a consensus site in the 150-loop region (highlighted
in green) is formed in open conformation. Consensus sites surrounding the Tamiflu binding region are present in all structures.
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rank of consensus sites, in terms of the number of clusters present,
located within the sialic acid, 150- and 430-loop regions were
fourth, second, and third, respectively. These rankings suggest that
the 150- and 430-loop regions represent druggable sites; the rela-
tionship between druggability and consensus site ranking is sup-
ported by a previous study (21).
Overall, comparing the mapping results shown in Figure 4, a signifi-
cant expansion in the volume occupied by probe clusters within the
430- and 150-loop regions is observed for both MD ensembles, sug-
gesting that the loop can be stabilized in multiple conformations
that would be amendable to ligand design. In Figure 6, we distin-
guish the mapping results for the open (Figure 6A and B) and wide-
open (Figure 6C and D) holo MD-generated conformations. From Fig-
ure 6, we conclude that although a hot spot is found within the
430-loop region of the wide-open conformations, further opening of
the loop results in its disappearance.
Table 2 provides statistics on the average sizes, in terms of cluster
population, and cluster energy rankings of consensus sites found
within each of the three binding regions for the representative MD
ensemble structures. Consensus sites were formed in the 150-loop
region for 9 of the 10 representative apo conformations; the only
apo conformation that did not contain a consensus site in the 150-
loop region was the closed conformation of the 150-loop. Similarly,
four of the five representative holo conformations contained con-
sensus sites within the 150-loop region with the exception of the
closed conformation. Within the 430-loop region, consensus sites
were not observed in three of the representative apo conformations
and one of the representative holo conformations, which is attrib-
uted to structural effects of the wide-open and closed conforma-
tions. Based on this data, we hypothesize that hot spots formed
within the 150- and 430-loop binding regions are roughly compara-
ble in terms of their ability to bind a variety of probe types with
good affinity; however, given the effects of loop dynamics on hot
Table 2: Summary of mapping results for the MD ensembles
MD ensemble Sialic acid 150-loop 430-loop
Apo 7(3) 13(5) 12(3)
Holo 8(2) 11(5) 11(3)
The average number of fragment clusters populating each binding region is
reported along with the average energy ranking of each fragment cluster in
parentheses.
A
C
B
D
Figure 6: Mapping reveals the
effects of loop conformation on
hot spot formation within the 430-
loop (highlighted in red) and 150-
loop (highlighted in green) binding
regions. A-B) Loop conformations
most resembling the open apo
conformation of the 150-loop yield
strong hot spots within both the
150-loop and the 430-loop regions.
C-D) Further opening of both loops
results in an eventual loss of a hot
spot within the 430-loop region.
Table 3: Residues predicted to mediate ligand contacts based on CS-Map results
Binding Region Residues predicted to mediate non-bonded ligand contacts Residues predicted to mediate hydrogen-bonded ligand contacts
Sialic acid R118, E119, R224, E227, E277, R371* E227*, S246, E277*, R371*, Y406*
150-loop V116, Q136*, V149, D151, R152, S153, P154, R156, W178, S195, G196 Q136*, D151*, R152, R156, W178, S179, G196,
430-loop I427*, R428, R430, P431, K432*, T439* S404, R430, K432, T439*
Residues marked with an asterisk (*) indicate the residues that account for greater than 5% of all atomic interactions made by mapped fragments within the
binding region. The program HBPLUS was used to calculate all atomic-level interactions occurring between fragments and residues.
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bly binds the 150-loop region when compared with the 430-loop
region.
Although the average affinity of probes for the sialic-acid binding
region is also very high (Table 2), the diversity of probes binding
in this region is significantly decreased when compared with
those binding to both of the loop regions. In particular, only the
most polar functional groups in the probe set – namely t-butanol,
isopropanol, and phenol – bind to the sialic acid binding region,
while nearly all probe types, both polar and non-polar, bind with
high affinity to the loop regions. This finding suggests that the
effects of charge on the bioavailability of N1 inhibitors may be alle-
viated by the addition of high-affinity, non-polar functional groups
that can bind one of the loop regions. We note that such insights
would not emerge from the application of CS-Map based on single,
static crystal structures only.
As the last part of this analysis, in Table 3, we provide a list of
residues predicted to significantly mediate either non-bonded
and⁄or hydrogen-bonded ligand contacts within the sialic acid, 430-
loop, and 150-loop binding regions. Using the 10 lowest Boltzmann
average free energy probe clusters determined for each holo MD
representative, all non-bonded and hydrogen-bonded atomic-level
contacts existing between residues of the binding region and the
mapped probes were calculated using the program HBPLUS (http://
www.biochem.ucl.ac.uk/bsm/hbplus) (46). Atomic interactions were
summed up for each residue and then normalized by the total num-
ber of interactions occurring within the binding region. In Table 3,
we report only those residues that account for at least 2% of the
total atomic-level interactions occurring within the binding region.
Residues marked with an asterisk indicate those accounting for
greater than 5% of all atomic-level probe-residue interactions.
Previous studies have established that protein–probe interactions
correlate strongly to known protein–ligand interactions (16,21). In
this study, the residues predicted to strongly mediate ligand con-
tacts within the sialic acid binding region – E227, E277, R371, and
Y406 – are well-known to be important in the binding of Tamiflu
and Relenza, suggesting that those predicted to mediate contacts
within the 130- and 430-loop regions – in particular, Q136, D151,
I437, K432, and T439 – are likely of importance in the development
of a novel class of high-affinity N1 inhibitors.
Conclusions
The influenza virus subtype H5N1 is of great concern because of its
high virulence and mutation rate, and some strains have already
acquired resistance to the currently available anti-influenza drugs
such as Tamiflu and Relenza. Two recent studies, one experimental
(8) and the other computational (14), uncovered flexibility within the
150- and 430-loop binding regions of N1, and these findings were
conjectured to provide new opportunities for drug design. Here, we
examined the effects of this newly discovered receptor flexibility on
the emergence of hot spots within these regions through the inte-
gration of extensive MD simulations, conformational clustering, and
CS-Map. We have identified novel hot spots within flexible binding
regions of the N1 neuraminidase and shown that such a clustering
procedure significantly improves the efficiency of the CS-Map appli-
cation.
Few computational methods can account for the effects of receptor
flexibility, although its importance is well-established (47–49).
Recent examples include the development of inhibitors for MAP
kinase p38 (50) and PTP1B (51) that have entered clinical trials and
the recently approved HIV integrase inhibitor, raltegravir (marketed
as Isentress, Merck, Whitehouse Station, NJ, USA) (52,53). Despite
these difficulties, by using a multi-faceted approach, we were able
to predict the emergence of stable hot spots within the 150- and
430-loop regions of N1. These results provide further support
for the feasibility of developing high-affinity inhibitors capable
of binding these newly proposed areas. We hypothesize that a puta-
tive novel class of inhibitors, which are able to exploit these new
hot spots, may potentially exhibit increased oral bioavailability and
be less susceptible to structural mutations in N1 and⁄or evade
existing mutations raised in response to currently available drugs.
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